We have located links that may give you full text access.
Journal Article
Research Support, Non-U.S. Gov't
Regional variation in the management of acute myocardial infarction in the province of Quebec.
Canadian Journal of Cardiology 2002 October
BACKGROUND: Previous studies have shown that there are differences in acute myocardial infarction (AMI) management in Canada and in the United States. However, there has been little research to evaluate regional variations in AMI treatment and outcomes for Canadian patients.
OBJECTIVE: To determine whether regional variation in the management of AMI in Quebec has an impact on patient mortality and morbidity.
PATIENTS AND METHODS: Discharge summary and physician claims databases for 76,012 patients with AMI were used between January 1, 1988 and December 31, 1995 to build 16 cohorts for the administrative regions of the province of Quebec. The clinical characteristics, prescription medications, cardiac procedure use, readmissions for cardiac complications and mortality across the different regions were compared.
RESULTS: After adjusting for age and sex, discharge prescriptions resulted in the following ranges: angiotensin-converting enzyme inhibitors 34% to 46% of patients, acetylsalicylic acid 49% to 77%, beta-blockers 32% to 54%, calcium channel blockers 25% to 48%, lipid-lowering drugs 4% to 16% and nitrates 76% to 86%. Procedure use varied considerably across the province during the initial 10 days post-AMI (catheterization 3% to 28%; percutaneous coronary intervention 1% to 8%, and coronary artery bypass surgery 0 to 2%), as well as one year after discharge (27% to 47%, 8% to 17%, and 6% to 12%, respectively). Some variation was observed for cardiac complications after one year (unstable angina 9% to 21%; congestive heart failure and recurrent myocardial infarction, no major variation). However, there was no significant regional variation observed for one-year and three-year mortality rates (19% to 22% and 27% to 31%, respectively).
CONCLUSIONS: There was marked regional variation in the rates of discharge prescriptions for cardiac medications and cardiac procedures in patients who have had an AMI in Quebec. These results suggest that the type of treatment received for an AMI depends on the region in which the patient lives. This variation appeared to affect readmission rates for unstable angina, but had no impact on mortality or other cardiac complications post-AMI.
OBJECTIVE: To determine whether regional variation in the management of AMI in Quebec has an impact on patient mortality and morbidity.
PATIENTS AND METHODS: Discharge summary and physician claims databases for 76,012 patients with AMI were used between January 1, 1988 and December 31, 1995 to build 16 cohorts for the administrative regions of the province of Quebec. The clinical characteristics, prescription medications, cardiac procedure use, readmissions for cardiac complications and mortality across the different regions were compared.
RESULTS: After adjusting for age and sex, discharge prescriptions resulted in the following ranges: angiotensin-converting enzyme inhibitors 34% to 46% of patients, acetylsalicylic acid 49% to 77%, beta-blockers 32% to 54%, calcium channel blockers 25% to 48%, lipid-lowering drugs 4% to 16% and nitrates 76% to 86%. Procedure use varied considerably across the province during the initial 10 days post-AMI (catheterization 3% to 28%; percutaneous coronary intervention 1% to 8%, and coronary artery bypass surgery 0 to 2%), as well as one year after discharge (27% to 47%, 8% to 17%, and 6% to 12%, respectively). Some variation was observed for cardiac complications after one year (unstable angina 9% to 21%; congestive heart failure and recurrent myocardial infarction, no major variation). However, there was no significant regional variation observed for one-year and three-year mortality rates (19% to 22% and 27% to 31%, respectively).
CONCLUSIONS: There was marked regional variation in the rates of discharge prescriptions for cardiac medications and cardiac procedures in patients who have had an AMI in Quebec. These results suggest that the type of treatment received for an AMI depends on the region in which the patient lives. This variation appeared to affect readmission rates for unstable angina, but had no impact on mortality or other cardiac complications post-AMI.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app